Valuation: Exelixis, Inc.

Market Cap 14.58B 13.01B 12.12B 11.03B 20.77B 1,404B 20.92B 146B 56.97B 717B 54.74B 53.56B 2,304B P/E 2026 *
18.2x
P/E 2027 * 15.1x
Enterprise Value 13.84B 12.34B 11.5B 10.47B 19.71B 1,333B 19.86B 139B 54.07B 680B 51.95B 50.83B 2,186B EV / Sales 2026 *
5.42x
EV / Sales 2027 * 4.47x
Free-Float
98.15%
Yield 2026 *
-
Yield 2027 * -
1 day+0.79%
1 week+0.82%
Current month+0.75%
1 month-0.27%
3 months+5.37%
6 months+34.12%
Current year+34.27%
1 week 57.76
Extreme 57.76
61.14
1 month 54.54
Extreme 54.545
61.14
Current year 39.71
Extreme 39.71
61.14
1 year 33.76
Extreme 33.755
61.14
3 years 18.64
Extreme 18.64
61.14
5 years 14.87
Extreme 14.87
61.14
10 years 10.04
Extreme 10.04
61.14
Manager TitleAgeSince
Chief Executive Officer 65 22/07/2010
Director of Finance/CFO 58 15/07/2015
Chief Operating Officer 63 01/02/2016
Director TitleAgeSince
Director/Board Member 70 01/02/2004
Director/Board Member 82 01/08/2004
Chairman 77 01/01/1998
Date Insider Type Main position Quantity % Market Cap. Importance
8/10/26 A Sell

Director

-9,812 0.0039%
6/1/26 A Sell

Director

-9,812 0.0039%
6/1/26 A Sell

Director

-3,925 0.0016%
Change 5-day change 1-year change 3-year change Capi.($)
+0.79%+0.82%+46.79%+165.81% 14.47B
+4.16%+3.42%+49.37%+94.17% 74.16B
-0.37%-3.81%+19.75%+78.12% 57.39B
+1.63%-1.61%+3.83%+36.89% 47.64B
+0.50%+2.94%+344.62%+722.17% 44.29B
+3.05%-1.80%+28.78%+34.51% 42.5B
+1.00%-1.46%+5.17%+111.90% 40.71B
-0.54%+2.41%+9.31%+58.85% 30.97B
+4.42%+8.04%+37.62%+32.27% 28.53B
+0.76%-1.45%-7.44%-11.12% 24.34B
Average +1.53%-0.04%+53.78%+132.36% 40.5B
Weighted average by Cap. +1.71%-0.36%+58.10%+138.53%

Financials

2026 *2027 *
Net sales 2.55B 2.28B 2.12B 1.93B 3.64B 246B 3.67B 25.66B 9.98B 126B 9.59B 9.38B 404B 2.9B 2.58B 2.41B 2.19B 4.13B 279B 4.16B 29.08B 11.32B 142B 10.87B 10.64B 458B
Net income 820M 732M 682M 620M 1.17B 79B 1.18B 8.24B 3.2B 40.32B 3.08B 3.01B 130B 1B 895M 833M 758M 1.43B 96.58B 1.44B 10.07B 3.92B 49.29B 3.76B 3.68B 158B
Net Debt -744M -664M -619M -563M -1.06B -71.7B -1.07B -7.48B -2.91B -36.59B -2.79B -2.73B -118B -1.62B -1.45B -1.35B -1.23B -2.31B -156B -2.33B -16.3B -6.34B -79.76B -6.09B -5.96B -256B
Logo Exelixis, Inc.
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Employees
1,077
Date Price Change Volume
05/10/26 $58.85 +0.79% 2,580,702
02/10/26 $58.39 +0.78% 1,969,279
01/10/26 $57.94 -0.80% 1,369,460
30/09/26 $58.41 -0.41% 3,065,021
29/09/26 $58.65 +0.48% 2,244,178
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
58.85USD
Average target price
54.13USD
Spread / Average Target
-8.01%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EXEL Stock